91 results on '"Cheng W"'
Search Results
2. Does thyroid dysfunction predict sustained virological response in triple therapy regimes with protease inhibitors in hepatitis C genotype 1 patients?
3. Does lamivudine have a role in the management of chronic Hepatitis B in pregnant woman with normal ALT?
4. Changing trends in acute viral hepatitis associated hospitalizations in a tertiary hospital
5. Impact of introduction of Fibroscan® on the change in management of patients with Chronic Hepatitis C (CHC) infection
6. The changing profile of patients with chronic Hepatitis c infection treated at a tertiary center in western Australia over the last decade
7. The correlation between Hepascore and Fibroscan® in patients with chronic viral hepatitis
8. The effects of tenofovir and entecavir on renal function in patients with chronic hepatitis b treated for two years at a tertiary center
9. Elderly age is not associated with reduced sustained virological response in the treatment of genotype 1 chronic Hepatitis C infection
10. Successful treatment of patients with chronic hepatitis C genotype 1 with triple therapy using direct antiviral agents, in rural and remote regional Western Australia (WA)
11. Factors associated with compliance and adherence in the treatment of chronic hepatitis c infection at a tertiary center
12. Long-term “real world” experience with entecavir and tenofovir in the treatment of chronic hepatitis B: A Western Australian tertiary center experience
13. Long term follow-up of patients treated with sofosbuvir in the phase 3 studies FISSION, POSITRON, FUSION and NEUTRINO
14. Real world efficacy and safety with direct acting antiviral drugs in chronic hepatitis C – Western Australian experience
15. Development of autoimmune type I diabetes mellitus during treatment with peginterferon and ribavirin for chronic hepatitis C – a tertiary center experience
16. Good transient elastography inter-observer reproducibility in a nurse-led FibroScan clinic at a single tertiary center
17. The changing risk factor profile of hepatocellular carcinoma: experiences from a Western Australian Tertiary Center
18. Treatment safety and efficacy of boceprevir-based triple therapy in genotype 1 hepatitis C: the Australian multicenter boceprevir real world experience (SABRE-C)
19. Tenofovir and Pegylated Interferon combination therapy for HBeAg positive chronic hepatitis B: a randomised, open label pilot study
20. IL28B genotype frequency in Australian patients with genotype 2/3 HCV differs from that observed in genotype 1 HCV: Interim analysis of the GUIDE study
21. RBV pharmacokinetics explain the relationship between on-treatment anaemia and SVR, which is independent of ITPA genotype: analysis from the CHARIOT study
22. Does stage of liver disease affect response in chronic hepatitis B patients treated with entecavir?
23. Predictors of virological suppression and its association with HBeAg seroconversion in chronic hepatitis B patients treated with entecavir
24. Early experience on treatment with direct acting antiviral drugs in chronic hepatitis C – interim analysis in Western Australian tertiary centres
25. Direct acting antiviral drugs in chronic hepatitis C and renal toxicity
26. Hepatitis C & Porphyria Cutanea Tarda- experience in 2 tertiary centres
27. Management of chronic hepatitis B in pregnancy – tenofovir or lamivudine?
28. Nurse-led hepatocellular carcinoma surveillance clinic provides an effective method of monitoring patients with cirrhosis
29. Association of IFNL3 polymorphisms with fibrosis progression in viral and non-viral chronic liver disease
30. Management of chronic hepatitis B with Tenofovir Disoproxil Fumarate is not associated with significant renal toxicity
31. The treatment of chronic hepatitis c in patients on maintenance dialysis in australia: Preliminary results
32. Efficacy and tolerability of Moviprep compared to Colonlytely in patients undergoing colonoscopy in a Day-Endoscopy Unit
33. Evaluation of treatment of chronic hepatitis B with peg-interferon in a major tertiary hospital in Western Australia
34. Evaluation of HCV treatment in rural and remote areas in Western Australia via telemedicine
35. Very low endogenous levels of MxA heptocellular protein suggest minimal activation of the type 1 interferon pathway in chronic HBV disease
36. Hepatitis C in pregnancy in Western Australia: a cross-sectional study
37. Dangers of IV drug use during hepatitis C treatment: coincidence or common knowledge?
38. Long-term Lamivudine: experience in hepatitis B patients in a tertiary centre in Western Australia
39. Admissions of indigenous patients with chronic liver disease to a tertiary hospital in western Australia
40. Hedgehog signalling down regulated in celiac disease
41. Accuracy of non-invasive measures in detecting advanced fibrosis and cirrhosis in chronic hepatitis B patients
42. Retreatment of chronic hepatitis C (CHC): outcomes and factors predicting outcomes
43. Is treatment-related anaemia associated with achievement of sustained virological response in patients with genotype 1 hepatitis C?
44. Treatment adherence and post treatment follow up for treatment of chronic HCV infection
45. The prevalence of insulin resistance in HCVinfected patients and its association with treatment outcomes
46. Sustained virological response rates and predictors of treatment success at Royal Perth Hospital with pegylated interferon and ribavirin from 2001 to 2009
47. Outcomes post acute variceal haemorrhage in a large inner city hospital
48. Telehealth in management of chronic hepatitis C in rural and remote areas—patientsʼ perspective
49. Outcomes of treatment of hepatitis C cirrhosis with pegylated interferon-alpha and ribavirin
50. Life-threatening bone marrow suppression with interferon alpha treatment in viral hepatitis
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.